Developer docs
API playgroundTry for free, no card

Search company profiles

Ybrain

Full company profile

uuid0002vfi

Namestring
Ybrain
Legal namestring
주식회사 와이브레인
Websiteurl
ybrain.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Ybrain (주식회사 와이브레인) is a South Korean neurotechnology company founded in 2013 that develops and commercializes non-invasive brain stimulation medical devices for diagnosing and treating neuropsychiatric conditions, primarily depression and migraine. Its core technology stack combines transcranial electrical stimulation (tES/tDCS), transcranial nerve stimulation (tNS), and electroencephalography (EEG) into a hospital-to-home treatment platform branded as MINDD. The product portfolio includes MINDD STIM+ (FDA PMA-approved tDCS device for depression, 62.8% remission rate in 6-week home treatment), MINDD SCAN (wireless EEG diagnostic system), DOOPANG/두팡 (TENS device for migraine, 61.7% pain relief within 2 hours), KLAR (mental wellness self-care app), and POLA (consumer device line). Ybrain holds 45+ domestic and international patents and has secured the only three MFDS-approved confirmatory clinical trials for electronic drugs in Korea, plus 21 exploratory trials.

The company operates a multi-channel go-to-market model combining B2B direct sales to hospitals and psychiatric clinics with B2C e-commerce (shop.ybrain.com), a B2B medical institution portal (bizshop.ybrain.com), pharmacy distribution, and retail partnerships including GS Shop live shopping. Revenue is generated primarily through hardware device sales and recurring consumables (hydrogel patches), supplemented by subscription-based clinic services. MINDD STIM+ requires prescription and is distributed through medical channels, while Doopang is available direct-to-consumer without prescription. The company has achieved substantial Korean market penetration with solutions deployed across 767 psychiatric clinics (approximately 35% of Korea's psychiatry departments), 250+ partner hospitals, and cumulative prescription/measurement records exceeding 1.4 million cases. Ybrain is pursuing FDA approval for the U.S. market and has raised 33.6 billion KRW (~$25M) in total funding, including an 11 billion KRW pre-IPO round in February 2022 from Ceragem, Intervest, and KT&G, with plans for a KOSDAQ listing. The company is headquartered in Seongnam (Pangyo Techno Valley) with manufacturing in Daejeon and operates with 11-50 employees.

Short descriptiontext

Ybrain is a South Korean neurotech company that develops non-invasive brain stimulation medical devices (tDCS, TENS, EEG) for diagnosing and treating depression and migraine, serving psychiatric hospitals, clinics, and consumers across Korea with hospital-to-home treatment platforms.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeongnam, South Korea
HQ citystring
Seongnam
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
non-invasive brain stimulation, depression treatment devices, neuromodulation medical devices, EEG brain measurement systems, mental health platforms
Industry3 codes
PRIMARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAKAIAE
Headache & Migraine Medicine
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Other Ambulatory Health Care Services6219
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Neuromodulation medical devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Medical Device Sales
TypeHardware Sales
Description

Sale of electronic drug medical devices (MINDD STIM+, Doopang, MINDD SCAN) to hospitals, clinics, and consumers. Devices sold directly through e-commerce platforms and medical institution portals, with B2B channel through bizshop for medical institutions.

shop.ybrain.com
2Consumables and Accessories
TypeHardware Sales
Description

Recurring revenue from consumable patches (hydrogel patches) for Doopang and MINDD STIM+ devices. Patches typically last approximately 10 uses per unit.

shop.ybrain.com
3Clinic/Professional Services
TypeSubscription Recurring
Description

MINDD platform providing total mental health solutions to medical institutions including brain wave scanning, stimulation treatment, and data management.

shop.ybrain.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details5 tiers
1Doopang Pro - Device + 15 patches
ModelUnit PricingBilling cadencePay-as-you-go
Notes

368,000 KRW for Doopang Pro device bundle including 15 hydrogel patches

shop.ybrain.com
2Doopang Starter - Device + 3 patches
ModelUnit PricingBilling cadencePay-as-you-go
Notes

298,000 KRW for Doopang Starter device bundle including 3 hydrogel patches

shop.ybrain.com
3Doopang Hydrogel Patches - 12 pieces
ModelUnit PricingBilling cadencePay-as-you-go
Notes

120,000 KRW for pack of 12 replacement hydrogel patches

shop.ybrain.com
4Doopang Hydrogel Patches - 3 pieces
ModelUnit PricingBilling cadencePay-as-you-go
Notes

33,000 KRW for pack of 3 replacement hydrogel patches

shop.ybrain.com
5Doopang Hydrogel Patch - single unit
ModelUnit PricingBilling cadencePay-as-you-go
Notes

12,000 KRW per individual hydrogel patch

shop.ybrain.com
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1MINDD
Description

Platform brand encompassing MINDD STIM+ (depression treatment device) and MINDD SCAN (brain wave measurement system)

ybrain.com
+5 more records
Core offering1 text field

Ybrain designs, manufactures, and sells non-invasive brain stimulation medical devices (electronic drugs) and an integrated mental healthcare platform for the diagnosis and treatment of neuropsychiatric conditions. Its core commercial products are MINDD STIM+ (a tDCS device for major depressive disorder with 62.8% remission rate), MINDD SCAN (a wireless EEG measurement and diagnostic system), and DOOPANG (a TENS device for migraine relief with 61.7% pain relief rate), supported by the KLAR self-care app and the broader MINDD platform for hospital-home linked treatment and data-based symptom management.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 62.8% remission rate in 6-week home-based depression treatment with MINDD STIM+
+4 more records
Product overview1 text field

Ybrain is a mental healthcare technology company offering an integrated platform of electronic drug (전자약) products based on non-invasive brain stimulation technologies. The core product portfolio consists of MINDD STIM+ (tDCS device for depression treatment), MINDD SCAN (wireless EEG brain measurement system), DOOPANG (TENS device for migraine relief), and KLAR (self-care mental wellness app). These products are unified under the MINDD platform, which provides hospital-home linked brain stimulation therapy with data-based personalized symptom management. Ybrain's solutions cover the full mental healthcare spectrum from diagnosis (EEG, HRV testing) to treatment (tDCS, TENS) and ongoing self-care management.

Product and service4 records
1MINDD STIM+
CategoryNon-invasive brain stimulation medical device (tDCS electronic drug)
Description

A transcranial Direct Current Stimulation (tDCS) medical device that delivers micro-current-based neural regulation to treat depression and other psychiatric conditions. FDA-approved under PMA pathway and MFDS-approved, clinically validated with 62.8% remission rate in 6-week home-based treatment trials. Prescribed by psychiatrists and used in hospitals and at home.

2MINDD SCAN
CategoryEEG-based brain wave measurement / diagnostic medical device
Description

A wireless EEG (electroencephalography) measurement system that enables rapid brain signal recording and real-time brain state analysis for diagnostic support. Supports one-stop non-invasive brain wave testing, HRV examination, and automated analysis reports for hospitals and clinics.

3DOOPANG (두팡)
CategoryTENS-based migraine relief medical device
Description

A TENS (Transcutaneous Electrical Nerve Stimulation) device for migraine relief and prevention. MFDS-approved medical device that reduces migraine frequency and alleviates pain, with 61.7% pain relief rate reported within 2 hours of use. Available directly to consumers without prescription through shop.ybrain.com, GS Shop, and pharmacies.

4MINDD Platform
CategoryMental healthcare platform for medical institutions
Description

An integrated mental healthcare platform combining MINDD STIM+, MINDD SCAN, and related services. Enables hospital-home linked brain stimulation therapy and supports data-based personalized symptom management for medical institutions. Deployed at 767 clinics covering 35% of South Korea's psychiatry departments with 140,000+ prescriptions and measurements.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1Korea BCCI Association
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-16
Description

Ybrain joined as founding member of the Korea Brain-Computer Interface Association, launched in Seoul on June 16. Association brings together industry, medical, and academic participants to advance BCI development under K-Moonshot program. Ybrain, along with Wybrain, Dynamic Solutions, and Serrajem, joined hospitals and universities as founding members. Association plans to develop industrial policies, support joint R&D, standardize activities internationally, and foster professionals.

mk.co.kr
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-02
Description

MOU signed June 2, 2026 for joint development of next-generation Brain-Computer Interface (BCI) technology. Partnership combines DGIST's biomedical engineering research infrastructure and GMP-certified facilities with Ybrain's neurotechnology and medical device commercialization capabilities. Aims to establish full-cycle cooperative framework from R&D to validation and commercialization of BCI technology, supporting the government's K-Moonshot initiative.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-10
Description

Strategic MOU for BCI technology commercialization. Development of precision control technology based on brain neural signals, BCI and AI robotics technology convergence for enabling paraplegic patients to control machines with thoughts, visual/auditory restoration technology, and applications in wearable robots, defense robots, and industrial robotics. Dynamic Solutions is the second-largest shareholder after Serrajem.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-11
Description

Ybrain signed business agreement as the sole industry partner in the brain-computer interface field for the Ministry's K-Moonshot project. The project involves 600 billion KRW in government funding. Ybrain will use its non-invasive brain stimulation technology and clinical data to establish technical standards and build a brain science ecosystem, with plans to develop invasive BCI commercialization to compete with Neuralink.

5Serrajem
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Largest shareholder in Ybrain. Serrajem joined Ybrain as a strategic partner and is currently the largest shareholder.

ybrain.com
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Joint sales partnership for MINDD STIM+ distribution through Jeil Pharma's pharmaceutical sales network, leveraging their CNS business network for hospital sales.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration with Professor Ji Il-joo's team for development of high-density wireless BCI system using 512-channel brain wave signal reading with mesh electrode attachment (partial brain implantation/partial invasive method).

Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ybrain

Neuromodulation medical devicesybrain.com

Ybrain is a South Korean neurotech company that develops non-invasive brain stimulation medical devices (tDCS, TENS, EEG) for diagnosing and treating depression and migraine, serving psychiatric hospitals, clinics, and consumers across Korea with hospital-to-home treatment platforms.

What Ybrain does

Ybrain (주식회사 와이브레인) is a South Korean neurotechnology company founded in 2013 that develops and commercializes non-invasive brain stimulation medical devices for diagnosing and treating neuropsychiatric conditions, primarily depression and migraine. Its core technology stack combines transcranial electrical stimulation (tES/tDCS), transcranial nerve stimulation (tNS), and electroencephalography (EEG) into a hospital-to-home treatment platform branded as MINDD. The product portfolio includes MINDD STIM+ (FDA PMA-approved tDCS device for depression, 62.8% remission rate in 6-week home treatment), MINDD SCAN (wireless EEG diagnostic system), DOOPANG/두팡 (TENS device for migraine, 61.7% pain relief within 2 hours), KLAR (mental wellness self-care app), and POLA (consumer device line). Ybrain holds 45+ domestic and international patents and has secured the only three MFDS-approved confirmatory clinical trials for electronic drugs in Korea, plus 21 exploratory trials.

The company operates a multi-channel go-to-market model combining B2B direct sales to hospitals and psychiatric clinics with B2C e-commerce (shop.ybrain.com), a B2B medical institution portal (bizshop.ybrain.com), pharmacy distribution, and retail partnerships including GS Shop live shopping. Revenue is generated primarily through hardware device sales and recurring consumables (hydrogel patches), supplemented by subscription-based clinic services. MINDD STIM+ requires prescription and is distributed through medical channels, while Doopang is available direct-to-consumer without prescription. The company has achieved substantial Korean market penetration with solutions deployed across 767 psychiatric clinics (approximately 35% of Korea's psychiatry departments), 250+ partner hospitals, and cumulative prescription/measurement records exceeding 1.4 million cases. Ybrain is pursuing FDA approval for the U.S. market and has raised 33.6 billion KRW (~$25M) in total funding, including an 11 billion KRW pre-IPO round in February 2022 from Ceragem, Intervest, and KT&G, with plans for a KOSDAQ listing. The company is headquartered in Seongnam (Pangyo Techno Valley) with manufacturing in Daejeon and operates with 11-50 employees.

Ybrain firmographics

Firmographics
Name
Ybrain
Legal name
주식회사 와이브레인
Website
https://ybrain.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Ybrain is a South Korean neurotech company that develops non-invasive brain stimulation medical devices (tDCS, TENS, EEG) for diagnosing and treating depression and migraine, serving psychiatric hospitals, clinics, and consumers across Korea with hospital-to-home treatment platforms.
Ownership category
akta.pro rank

Ybrain industry classification

Industry
Product category
Neuromodulation medical devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Other Ambulatory Health Care Services (6219)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAKAIAE
Headache & Migraine Medicine

Keywords

  • Non-invasive brain stimulation
  • Depression treatment devices
  • Neuromodulation medical devices
  • EEG brain measurement systems
  • Mental health platforms

Where Ybrain is headquartered

Location

Headquarters

HQ city
Seongnam
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

Ybrain business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Medical Device Sales: Sale of electronic drug medical devices (MINDD STIM+, Doopang, MINDD SCAN) to hospitals, clinics, and consumers. Devices sold directly through e-commerce platforms and medical institution portals, with B2B channel through bizshop for medical institutions.
  2. Consumables and Accessories: Recurring revenue from consumable patches (hydrogel patches) for Doopang and MINDD STIM+ devices. Patches typically last approximately 10 uses per unit.
  3. Clinic/Professional Services: MINDD platform providing total mental health solutions to medical institutions including brain wave scanning, stimulation treatment, and data management.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goDoopang Pro - Device + 15 patches
Unit PricingPay-as-you-goDoopang Starter - Device + 3 patches
Unit PricingPay-as-you-goDoopang Hydrogel Patches - 12 pieces
Unit PricingPay-as-you-goDoopang Hydrogel Patches - 3 pieces
Unit PricingPay-as-you-goDoopang Hydrogel Patch - single unit

Go-to-market motion1 record

Distribution channels5 records

Marketing channels7 records

Ybrain product offering

Product offering

Core offering

Ybrain designs, manufactures, and sells non-invasive brain stimulation medical devices (electronic drugs) and an integrated mental healthcare platform for the diagnosis and treatment of neuropsychiatric conditions. Its core commercial products are MINDD STIM+ (a tDCS device for major depressive disorder with 62.8% remission rate), MINDD SCAN (a wireless EEG measurement and diagnostic system), and DOOPANG (a TENS device for migraine relief with 61.7% pain relief rate), supported by the KLAR self-care app and the broader MINDD platform for hospital-home linked treatment and data-based symptom management.

Product overview

Ybrain is a mental healthcare technology company offering an integrated platform of electronic drug (전자약) products based on non-invasive brain stimulation technologies. The core product portfolio consists of MINDD STIM+ (tDCS device for depression treatment), MINDD SCAN (wireless EEG brain measurement system), DOOPANG (TENS device for migraine relief), and KLAR (self-care mental wellness app). These products are unified under the MINDD platform, which provides hospital-home linked brain stimulation therapy with data-based personalized symptom management. Ybrain's solutions cover the full mental healthcare spectrum from diagnosis (EEG, HRV testing) to treatment (tDCS, TENS) and ongoing self-care management.

Differentiator

Problem solved

Functional benefit

Brands

  • MINDD: Platform brand encompassing MINDD STIM+ (depression treatment device) and MINDD SCAN (brain wave measurement system)
  • DOOPANG (두팡)
  • KLAR
  • POLA
  • 전자약국
  • 전자약국 비즈샵

Products and services

  • MINDD STIM+ A transcranial Direct Current Stimulation (tDCS) medical device that delivers micro-current-based neural regulation to treat depression and other psychiatric conditions. FDA-approved under PMA pathway and MFDS-approved, clinically validated with 62.8% remission rate in 6-week home-based treatment trials. Prescribed by psychiatrists and used in hospitals and at home.
  • MINDD SCAN A wireless EEG (electroencephalography) measurement system that enables rapid brain signal recording and real-time brain state analysis for diagnostic support. Supports one-stop non-invasive brain wave testing, HRV examination, and automated analysis reports for hospitals and clinics.
  • DOOPANG (두팡) A TENS (Transcutaneous Electrical Nerve Stimulation) device for migraine relief and prevention. MFDS-approved medical device that reduces migraine frequency and alleviates pain, with 61.7% pain relief rate reported within 2 hours of use. Available directly to consumers without prescription through shop.ybrain.com, GS Shop, and pharmacies.
  • MINDD Platform An integrated mental healthcare platform combining MINDD STIM+, MINDD SCAN, and related services. Enables hospital-home linked brain stimulation therapy and supports data-based personalized symptom management for medical institutions. Deployed at 767 clinics covering 35% of South Korea's psychiatry departments with 140,000+ prescriptions and measurements.

Quantifiable outcome

  • 62.8% remission rate in 6-week home-based depression treatment with MINDD STIM+
  • +4 more outcomes

Companies that use Ybrain

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Ybrain technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Ybrain partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Korea BCCI AssociationcoreStrategic or Co-development Partner · 16 June 2026Ybrain joined as founding member of the Korea Brain-Computer Interface Association, launched in Seoul on June 16. Association brings together industry, medical, and academic participants to advance BCI development under K-Moonshot program. Ybrain, along with Wybrain, Dynamic Solutions, and Serrajem, joined hospitals and universities as founding members. Association plans to develop industrial policies, support joint R&D, standardize activities internationally, and foster professionals.
  • DGIST (Daegu Gyeongbuk Institute of Science and Technology)coreStrategic or Co-development Partner · 2 June 2026MOU signed June 2, 2026 for joint development of next-generation Brain-Computer Interface (BCI) technology. Partnership combines DGIST's biomedical engineering research infrastructure and GMP-certified facilities with Ybrain's neurotechnology and medical device commercialization capabilities. Aims to establish full-cycle cooperative framework from R&D to validation and commercialization of BCI technology, supporting the government's K-Moonshot initiative.
  • Dynamic SolutionscoreStrategic or Co-development Partner · 10 April 2026Strategic MOU for BCI technology commercialization. Development of precision control technology based on brain neural signals, BCI and AI robotics technology convergence for enabling paraplegic patients to control machines with thoughts, visual/auditory restoration technology, and applications in wearable robots, defense robots, and industrial robotics. Dynamic Solutions is the second-largest shareholder after Serrajem.
  • Ministry of Science and ICT (K-Moonshot Project)coreStrategic or Co-development Partner · 11 March 2026Ybrain signed business agreement as the sole industry partner in the brain-computer interface field for the Ministry's K-Moonshot project. The project involves 600 billion KRW in government funding. Ybrain will use its non-invasive brain stimulation technology and clinical data to establish technical standards and build a brain science ecosystem, with plans to develop invasive BCI commercialization to compete with Neuralink.
  • SerrajemminorStrategic or Co-development PartnerLargest shareholder in Ybrain. Serrajem joined Ybrain as a strategic partner and is currently the largest shareholder.
  • Jeil Pharma (종근당)minorChannel Partner/ Reseller/ DistributorJoint sales partnership for MINDD STIM+ distribution through Jeil Pharma's pharmaceutical sales network, leveraging their CNS business network for hospital sales.
  • Korea University ( 고려대학교)minorStrategic or Co-development PartnerCollaboration with Professor Ji Il-joo's team for development of high-density wireless BCI system using 512-channel brain wave signal reading with mesh electrode attachment (partial brain implantation/partial invasive method).

Scale indicators14 records

Recent moves2 records

Expansion highlights6 records

Ybrain competitors and assessment

Company assessment

Market position

Strengths5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Ybrain social profiles

Digital presence

Ybrain financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ybrain leadership team

Management profile

Number of profiles

Profiles3 records

Ybrain funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ybrain M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ybrain

What does Ybrain do?

Ybrain designs, manufactures, and sells non-invasive brain stimulation medical devices (electronic drugs) and an integrated mental healthcare platform for the diagnosis and treatment of neuropsychiatric conditions. Its core commercial products are MINDD STIM+ (a tDCS device for major depressive disorder with 62.8% remission rate), MINDD SCAN (a wireless EEG measurement and diagnostic system), and DOOPANG (a TENS device for migraine relief with 61.7% pain relief rate), supported by the KLAR self-care app and the broader MINDD platform for hospital-home linked treatment and data-based symptom management.

Is Ybrain a public or private company?

Ybrain is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ybrain founded?

Ybrain was founded in 2013. It employs 11 to 50 people.

Where is Ybrain based?

Ybrain is headquartered in Seongnam, South Korea, in the Asia region.

How does Ybrain make money?

Three revenue lines are on record. Medical Device Sales are the primary driver. The others are consumables and Accessories and clinic/Professional Services.

Does Ybrain have an API?

No public API is recorded for Ybrain.

What industry is Ybrain in?

Ybrain's product category is Neuromodulation medical devices. Its primary akta.pro industry code is HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables), with a secondary code of HLACANAI, Behavioral Health & Neurocognitive Therapeutics (Digital). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Asiae'Commands by Mind, Instantly Executed'... Ybrain Takes on Challenge to Commercialize BCI by 2035Ybrain, a South Korean electroceutical and brain-computer interface developer, co-hosted the BCI Alliance Launch Ceremony at Seoul's Plaza Hotel on August 26, with the Ministry of Science and ICT, the National Research Foundation of Korea, the Korea Brain Research Institute and the Korea BCI Association. The company, which has 13 years of BCI development and over 1.4 million clinical brain data points, will share its clinical and commercialization expertise across R&D, commercialization and infrastructure divisions.스타트업엔(StartupN)Wavbrain and Korea Pharma join hands... Targeting the mental health market with AI brainwave diagnosis and electronic medicine.Y-Brain and Korea Pharma signed a joint business contract for the AI brainwave diagnostic system Mind Scan and electronic medicine Mind Stim. Korea Pharma will distribute the products nationwide, using its CNS treatment network. The collaboration aims to expand domestic mental health device distribution and prepare for overseas expansion.KBRKorea launches BCI industry association to boost global competitivenessThe Korea BCI Association officially launched this week at Centerfield in Seoul, bringing together industry, healthcare, and academic stakeholders to support the growth of Korea's brain-computer interface sector. Founding corporate members include Ybrain, Dynamic Solution, Vivat Robotics, and CERAGEM, alongside healthcare institutions such as Seoul National University Hospital, Severance Hospital, and Korea University Anam Hospital, as well as academic members including KAIST, DGIST, UNIST, Korea University, Catholic Kwandong University, Yonsei University, and Hanyang University. The association aims to accelerate BCI research, commercialization, and standardization efforts while supporting the government's K-Moonshot Project for next-generation BCI technologies.MkSouth Korea is entering the brain-computer interface (BCCI) industry in earnest. Following the gover..The Korea BCCI Association was officially launched in Seoul on the 16th, bringing together industry, medical, and academic participants to advance brain-computer interface development in South Korea under the K-Moonshot program. Paik Nam-jong, president of Seoul National University Hospital, was appointed as the association's first president, while companies including Wybrain, Y-Brain, Dynamic Solutions, and Serrajem joined hospitals and universities as founding members. The association plans to develop industrial policies, support joint R&D, standardize activities internationally, and foster professionals to position Korea as a global BCCI powerhouse.AsiaresearchnewsDGIST Signs MOU with Ybrain to Advance Next-Generation Brain–Computer Interface ResearchDGIST and Ybrain signed a memorandum of understanding on June 2 to jointly develop next-generation Brain-Computer Interface (BCI) technology, combining DGIST's biomedical engineering research infrastructure and GMP-certified facilities with Ybrain's neurotechnology and medical device commercialization capabilities. The partnership aims to expand Korea's research and validation base for the BCI industry while supporting the government's "K-Moonshot" initiative for breakthrough technological innovation. The agreement establishes a full-cycle cooperative framework from R&D to validation and commercialization of BCI technology, expected to contribute to national strategic technologies in medicine, rehabilitation, robotics, and artificial intelligence.VenturesquareExpanding the K-Moonshot-based neuroscience ecosystem... Y-Brain and Digist collaborate on next-generation BCI development.Ybrain and DGIST signed an MOU on April 4 to develop next-generation brain-computer interfaces and share research infrastructure. The collaboration aims to accelerate BCI commercialization, leveraging Ybrain's 13-year neural signal analysis and 1.4 million data points. Both leaders cited the K-Moonshot Project and global standards competition as key drivers.DigitaltodayYbrain joins K-Moonshot project as sole BCI industry partnerYbrain signed a business agreement to participate in the Ministry of Science and ICT's K-Moonshot project as the sole industry partner in the brain-computer interface field. The company will use its non-invasive brain stimulation technology and clinical data to establish technical standards and build a brain science ecosystem, with its solutions already deployed at 767 clinics covering 35 percent of South Korea's psychiatry departments. Ybrain plans to accelerate next-generation BCI development to compete with Elon Musk's Neuralink and expand into invasive BCI commercialization.PR NewswireYbrain Receives Translational Research Award 2022 Neuroergonomics Conference & NYC Neuromodulation ConferenceYbrain received the Translational Research Award at the 2022 Neuroergonomics Conference & NYC Neuromodulation Conference (July 28–August 1, 2022) for its transcranial direct current stimulation (tDCS) neuromodulation technology designed to treat major depressive disorder. Only two out of dozens of renowned neuromodulation scholars received this award, which recognizes significant contributions to the field. Ybrain has submitted its MINDD-STIM+ device for FDA De Novo clearance, expected in early 2023, as part of its strategy to penetrate the US market with an at-home electroceutical alternative to antidepressants.Wismax[WiseMax News] Wibrain Completes 11 Billion Won Pre-IPO Investment AttractionY-Brain, an affiliate of Neofect, has completed a pre-IPO investment round of 11 billion won with participation from Ceragem, Intervest, and KT&G. This funding brings Y-Brain's cumulative investment to 33.6 billion won as the company prepares for a domestic listing this year and aims for FDA approval in the U.S. Strategic investors Ceragem and KT&G plan to collaborate on future electronic drug businesses, supporting Y-Brain's expansion into global markets.PharmnewsWibrain, an electronic drug platform company, has completed a 11 billion won pre-IPO investment attraction - Farm NewsY-Brain completed an 11 billion won pre-IPO investment round, bringing its cumulative funding to 33.6 billion won, with strategic participation from Ceragem and KT&G. The company plans to use the funds to accelerate FDA approval in the U.S. and pursue a technical listing in Korea by the end of the year.